

K231161 0.9% Sodium Chloride Injection, USP BD PosiFlush™ SF Saline Flush Syringe

Jul 21, 2023
88 days to decisionK231161 · Product code: **NGT** · General Hospital
Source: <https://www.510kdatabase.net/k231161/>

SUBMISSION DETAILS

| | |
|-----------------------|-------------------------------------|
| Decision | Substantially Equivalent (Cleared) |
| Submission type | Traditional |
| Device classification | Saline, Vascular Access Flush (NGT) |
| Date received | Apr 24, 2023 |
| Decision date | Jul 21, 2023 |
| Days to decision | 88 days |
| Third-party review | No |
| Combination product | No |
| PCCP authorized | No |
| Summary / Statement | Summary |

APPLICANT

| | |
|----------------|---|
| Company | Becton, Dickinson and Company |
| Location | Franklin Lakes, NJ, US |
| Contact | Samhitha Mohan |
| Website | https://www.bd.com |
| 510(k) history | 134 submissions · 134 cleared · 2010-2026 |

Becton, Dickinson and Company is an American multinational medical technology company headquartered in Franklin Lakes, New Jersey. BD manufactures and sells medical devices, instrument systems, and reagents globally. The company maintains a strong FDA 510(k) regulatory record with FDA 510(k) clearances from total submissions spanning 2010 to 2026. BD's cleared devices span multiple categories including microbiology systems, blood collection products, and general hospital devices. The company's latest clearance in 2026 reflects continued innovation and regulatory engagement...